Literature DB >> 27090545

A rare case of thyroid storm.

Brock McMillen1, Manvinder Shelley Dhillon1, Sabrina Yong-Yow1.   

Abstract

Thyroid storm is a rare and life-threatening state of thyroid hormone excess. Rapid recognition of thyroid storm is key to decreasing the morbidity and mortality of this condition. Clinical manifestations of thyroid storm include unexplained weight loss, hyperactivity and irritability. The most common causes of thyrotoxicosis are Graves' disease, toxic multinodular goitre and toxic adenoma. We present a rare case of thyroid storm induced by dual nivolumab and ipilimumab immunotherapy in a patient receiving treatment for advanced melanoma. In this case, our patient was admitted for thyroid storm 1 month after initiating treatment with nivolumab and ipilimumab immunotherapy. The patient was treated with β-blockers, antithyroid medications and systemic steroids resulting in an improvement in thyroid function testing and symptoms. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27090545      PMCID： PMC4840694          DOI： 10.1136/bcr-2016-214603

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  3 in total

1.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.

Authors:  Rebecca S Bahn; Henry B Burch; David S Cooper; Jeffrey R Garber; M Carol Greenlee; Irwin Klein; Peter Laurberg; I Ross McDougall; Victor M Montori; Scott A Rivkees; Douglas S Ross; Julie Ann Sosa; Marius N Stan
Journal:  Endocr Pract       Date:  2011 May-Jun       Impact factor: 3.443

2.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

3.  A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis.

Authors:  Christine Yu; Inder J Chopra; Edward Ha
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2015-02-01
  3 in total
  14 in total

1.  Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Authors:  Jaydira Del Rivero; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley
Journal:  Oncologist       Date:  2019-10-10

2.  Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Authors:  Jaydira Del Rivero; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley
Journal:  Oncologist       Date:  2019-10-10

Review 3.  The side effects of immune checkpoint inhibitor therapy on the endocrine system.

Authors:  Itivrita Goyal; Manu Raj Pandey; Rajeev Sharma; Ajay Chaudhuri; Paresh Dandona
Journal:  Indian J Med Res       Date:  2021-04       Impact factor: 5.274

4.  Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.

Authors:  Kazuko Yonezaki; Toshihiro Kobayashi; Hitomi Imachi; Takuo Yoshimoto; Fumi Kikuchi; Kensaku Fukunaga; Seisuke Sato; Tomohiro Ibata; Nao Yamaji; Jingya Lyu; Tao Dong; Koji Murao
Journal:  J Med Case Rep       Date:  2018-06-19

Review 5.  Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.

Authors:  Maria Stelmachowska-Banaś; Izabella Czajka-Oraniec
Journal:  Endocr Connect       Date:  2020-10       Impact factor: 3.335

Review 6.  Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.

Authors:  Shintaro Iwama; Tomoko Kobayashi; Hiroshi Arima
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-27

7.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.

Authors:  Romualdo Barroso-Sousa; William T Barry; Ana C Garrido-Castro; F Stephen Hodi; Le Min; Ian E Krop; Sara M Tolaney
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

Review 8.  Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.

Authors:  Eli P Darnell; Meghan J Mooradian; Erez N Baruch; Melis Yilmaz; Kerry L Reynolds
Journal:  Curr Oncol Rep       Date:  2020-03-21       Impact factor: 5.945

9.  SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy.

Authors:  C E Higham; A Olsson-Brown; P Carroll; T Cooksley; J Larkin; P Lorigan; D Morganstein; P J Trainer
Journal:  Endocr Connect       Date:  2018-07       Impact factor: 3.335

Review 10.  Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.

Authors:  Lian Duan; Linjie Wang; Hanping Wang; Xiaoyan Si; Li Zhang; Xiaowei Liu; Yue Li; Xiaoxiao Guo; Jiaxin Zhou; Huijuan Zhu; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-11       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.